Equulus is taking a transdiagnostic approach to the development of therapeutics for CNS disorders, transcending standard diagnostic categories and tied to disease-driving physiology.
Drawing on evidence suggesting that mental health conditions exhibit overlapping symptom clusters, our focus lies in addressing the root causes of CNS disorders.
Equulus employs innovative biomarkers to expedite the success of drug development - generating highly valued therapeutics that comprehensively treat target indications.
Leveraging our expertise in drug formulations and delivery methods across all programs, Equulus aims to optimize drug efficacy and enhance product value.
The result?
Increased development success and efficacious therapeutics treating the entirety of the disorder.
